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Abstract
Background: Caveolin-1 is thought to have an important impact on both signal transduction and
mediation of intracellular processes. Furthermore, it has been suggested that Caveolin-1 may
contribute to certain steps of carcinogenesis in various types of cancer. We examined the potential
clinical relevance of Caveolin-1 in normal, benign and malignant breast tissue specimens.
Methods: Using tissue microarray (TMA) technology cases of invasive breast cancer, DCIS, benign
breast disease (i.e. fibroadenoma, sclerosing adenosis, ductal hyperplasia and radial scar) and
normal breast tissue were evaluated for Caveolin-1 expression. Immunohistochemical staining with
an anti-Caveolin-1-antibody was performed. Staining intensity was quantified semiquantitatively. In
invasive lesions staining results were correlated with clinical and pathological data.
Results: No Caveolin-1 expression was observed in epithelial cells of normal breast tissue (n = 5),
benign breast disease (n = 295) and DCIS (n = 108). However, Caveolin-1 expression was found in
32 of 109 cases of invasive breast carcinomas (29.4%). Caveolin-1 expression in invasive breast
cancer could neither be correlated with survival parameters such as overall or disease-free survival
nor with established clinical and pathological markers.
Conclusion: In this study we demonstrated expression of Caveolin-1 in one third of invasive
breast cancers. A significant increase in Caveolin-1 expression was observed comparing invasive
breast cancer to both benign breast tissue and non-invasive breast cancer. Since inhibitors of
Caveolin-1 signalling are available, targeting Caveolin-1 in breast cancer may represent a potential
option for future breast cancer treatment.
Background
Invasive breast cancer is still the most common female
malignancy worldwide and more than 1 million women
are diagnosed with breast cancer each year [1]. Caveolae
are flask-shaped invaginations of the plasma membrane
with an average diameter of 50–100 nm. The members of
the Caveolin family comprise the essential protein com-
pound of caveolae and stabilize the asymmetric distribu-
tion of lipids in this particular region [2]. Caveolin-1 has
been found to interact with numerous proteins such as the
heterotrimeric G-proteins [3], ha-ras, the members of the
src-family of tyrosine kinases [4], and the endothelial
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nitrooxid-synthase (eNOS) [5]. Based on the formation of
heterooligomeric complexes between Caveolin-1 and
both integral membrane proteins and cytoplasmic signal-
ling molecules, the Caveolin-signalling hypothesis has
been established. It describes a process of compartmental-
ization of distinct signaling molecules exerting an impor-
tant impact on cell signalling pathways by coupling
activated receptors to secondary cellular effector systems
[6]. NIH3T3 cells transformed by oncogenes such as v-abl-
or h-ras show reduced or even complete absence of Cave-
olin-1-mRNA or -protein expression [7]. Hence, a
tumour-suppressive function of Caveolin-1 has been sug-
gested. However, in a significant number of tumour enti-
ties including carcinoma of the pancreas [8], squamous
cell carcinoma of the lung [9], renal cell carcinoma [10],
and carcinoma of the prostate [11], overexpression of
Caveolin-1 has been described.
With regards to breast cancer only limited and conflicting
data exists. Caveolin-1 has been reported to be downreg-
ulated in a number of human breast cancer cell lines as
well as in tumours derived from transgenic rodents with
breast cancer [12]. Loss of heterozygosity (LOH) at
7q31.1–7q31.2 has been shown to be a common event in
breast cancer and the presence of a tumour suppressor
gene had been suggested accordingly [13]. However,
Caveolin-1 expression could not be shown to correlate
with LOH at the CAV-1 locus [14]. Thus, the role of Cave-
olin-1 in breast cancer tumourigenesis and progression
still remains ill-defined.
The aim of this study was to comprehensively examine
expression of Caveolin-1 in different benign and malig-
nant breast tissues, including DCIS and invasive breast
cancer using tissue microarray (TMA) technology.
Methods
Patients
200 breast cancer specimens were obtained from patients
primarily diagnosed with breast carcinoma, who under-
went surgery at the Department of Gynaecology, Univer-
sity of Münster (Germany), between 1993 and 1995. The
corresponding formalin-fixed paraffin-embedded tissue-
specimens were obtained from the archives of the Ger-
hard-Domagk-Institute of Pathology (University Hospital
Münster). The series of breast carcinomas previously has
been characterized with respect to histopathological and
clinical parameters and expression of ER, PR, HER2 and
Mib-1 [15,16] (table 1). All of the 245 patients with inva-
sive breast cancer were treated with therapeutic surgery
(69 mastectomy and 155 wide local excision) and adju-
vant anthracycline-based chemotherapy, and those with
ER-positive tumours also received endocrine therapy. No
neoadjuvant chemotherapy was performed. Mean dis-
ease-free survival (DFS) was 83 ± 3 months (95%-CI 77–
90), mean overall survival (OS) 90 ± 3 months (95%CI
85–96).
We also studied 200 cases of DCIS. All cases were classi-
fied according to the criteria outlined by Holland et al.,
based on nuclear grading and architectural features [17].
With respect to this classification, cases were graduated as
low grade (n = 54), intermediate grade (n = 49), and high
grade (n = 94). The median age of patients was 59 years
(range 18–94 years) [18].
Furthermore, we included samples of normal breast tissue
(n = 5) obtained from patients undergoing reduction
mammoplasty, and a set of benign breast disease (n =
295) in the study. Benign lesions comprised cases of
fibroadenoma (n = 167), sclerosing adenosis (n = 93),
ductal hyperplasia (n = 33) and radial scar (n = 2).
Preparation of TMA
Routinely fixed paraffin-embedded tissue blocks contain-
ing tumours excised at the time of surgery were extracted
from the files of pathology laboratories, and served as
donor blocks for the TMAs. Tumour samples were arrayed
in analogy to the procedure formerly described by
Kononen et al., [19]. Briefly, for each sample three mor-
phologically representative tissue areas were defined
based on haematoxylin and eosin (HE)-stained sections.
From each of these three areas, a tissue cylinder was
punched out from the donor blocks using a precision
instrument (Beecher Instruments) and transferred pre-
cisely into a new recipient paraffin block (20 × 35 mm).
Each cylinder had a diameter of 0.6 mm.
Immunohistochemistry
3 µm sections from the TMA blocks were mounted on
polylysine-coated microslides, dewaxed and rehydrated.
For antigen retrieval, tissue slides were immersed in
Reveal Emulgator (Biocarta, Hamburg, Germany) and
boiled in a pressure cooker (103 kPa/15 psi for 5 min.).
Subsequently, the sections were washed in Aqua dest. and
Phosphate buffered saline (Sigma), and then subjected to
Aurion-BSA-c10% (Aurion, Wageningen, Netherlands) in
order to block unspecific binding-agents. This step was
followed by overnight exposure (4°C) to the primary
monoclonal mouse-IgG1-anti-Caveolin-1-antibody (BD
Biosciences Pharmingen, Heidelberg, Germany; clone
2297; dilution: 1:200). This antibody has been used and
validated previously by others [20,21]. After rinsing in
PBS, H2O2-containing methanol (concentration: 0.6%)
was applied to provide quenching of endogenous peroxi-
dase activity, followed by incubation with the bridging
goat anti-mouse-immunoglobulins conjugated with
horseradish peroxidase (HRP)-labelled dextran polymer
for one hour (DAKO Envision, HRP, Mouse). Final wash-
ing in PBS was then followed by visualization of the per-World Journal of Surgical Oncology 2007, 5:110 http://www.wjso.com/content/5/1/110
Page 3 of 9
(page number not for citation purposes)
oxidase enzyme using Vector SG Substrate Kit for HRP
(Vector Laboratories, Burlingame, CA, USA) as well as
nuclear counterstaining with haematoxylin. Positive
staining of smooth muscle cells or endothelium, known
to be abundant in Caveolin-1, served as positive control,
while the omission of primary antibody served as negative
control.
Microscopic analysis
Caveolin-1 expression was then evaluated in a semiquan-
titative manner. Only membranous with or without cyto-
plasmic staining was considered specific, which is in
concordance with previous studies [21]. Previous studies
have also reported on the use of nonneoplastic endothe-
lial cells as internal positive controls for immunohisto-
chemical Caveolin-1 expression analysis [21].
Accordingly, in our study entrapped vessels served as
internal positive control, revealing a positive staining for
Table 1: Characteristics of patients with invasive breast carcinomas
Parameter n %
Histologic type: infiltrating ductal 97 54.5
lobular 40 22.5
tubular 9 5.1
mucinous 4 2.2
medullary 4 2.2
mixed-type 24 13.5
unknown 22
pT-stage: pT1 76 42.7
pT2 55 30.9
pT3 13 7.3
pT4 34 19.1
pTx 22
pN-stage: pN0 94 54.3
pN1 66 38.2
pN2 13 7.5
pN3 0 0
pNx 27
cM-stage M0 156 87.7
M1 22 12.3
pMx 22
Grading: G1 16 9.0
G2 98 55.1
G3 64 35.9
unknown 22
ER expression positive 105 62.9
negative 62 37.1
unknown 33
PR expression positive 77 46.4
negative 89 53.6
unknown 34
HER2expression positive 15 8.9
negative 154 91.1
unknown 31
MIB-1 expression < 20% 105 62.5
≥ 20% 63 37.5
unknown 32World Journal of Surgical Oncology 2007, 5:110 http://www.wjso.com/content/5/1/110
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anti-Caveolin-1 antibody. Membrane staining was scored
on a four-tired scale from "0" (no staining), over "1+"
(weak staining), "2+" (moderate staining) to "3+" (strong
staining) (Figure 1A and 1B). Depending on the staining
procedure varying numbers of tissue cores were detached.
Others did not contain sufficient numbers of tumour
cells. Therefore, some cases could not be analyzed. In the
case of more than one evaluable tissue probe, mean
expression levels were obtained. Tumours assessed to
show no Caveolin-1 expression at all (staining score 0)
were defined as "Caveolin-1 negative", whereas weakly,
moderately and strongly stained tissue cores were taken
together as "Caveolin-1 positive". Evaluation of Caveolin-
1 staining was performed in a blinded manner without
knowledge of the assigned clinical data. Analysis of other
prognostic and predictive factors such as ER-, PR-, HER2-,
and MIB-1 expression was performed as described previ-
ously [16]. "MIB-1 positive" staining had been previously
defined as > 20% of the cells showing MIB-1 expression
[15,16].
Statistical analysis
Statistical analysis of obtained data was performed using
SPSS-Software. For 178 patients with primary invasive
breast cancer sufficient survival data could be obtained.
These patients were included in survival analysis. Kaplan-
Meier curves for DFS and OS were generated and com-
pared by log-rank test. Correlation analysis between Cave-
olin-1 expression and clinical and pathological data
including information on tumour staging (TNM stage),
histological grading, hormone receptor and HER2 status
was performed using cross-tables applying χ2 test.
Results
Caveolin-1 expression
Caveolin-1 expression could be determined in 109 of 200
cases of invasive breast cancers (54.5%). 32 cases of inva-
sive breast cancer (29.4%) were found to be positive for
Caveolin-1. Among these cases, 24 (22.0%) showed a
weak, 6 (5.5%) a moderate, and 2 (1.8%) a strong stain-
ing (Table 2; Figure 1A and 1B).
Caveolin-1 expression could be evaluated in 108 of 200
cases of DCIS (54.0%). Among these cases, none dis-
played a significant staining for Caveolin-1.
Caveolin-1 expression could be determined in 236 of 295
cases of benign breast disease (80.0%); in detail, 148 of
167 cases of fibroadenoma (88.6%), 65 of 93 cases of scle-
rosing adenosis (69.9%), 21 of 33 cases of ductal hyper-
plasia (63.6%) and both cases of radial scar (100%) could
be evaluated. Among these cases, none showed significant
expression of Caveolin-1 in the epithelial component of
the benign disease.
Evaluation of normal breast tissue samples showed no
expression of Caveolin-1 in breast epithelial cells. In
myoepithelial cells of ducts and lobuli as well as in blood
vessels, expression of Caveolin-1 was consistently found
in normal breast tissue as well as both benign breast dis-
eases and DCIS.
Correlation studies
Correlation studies performed in the cases of invasive
breast cancer showed that none of the clinical and patho-
Caveolin-1 expression in breast cancer samples Figure 1
Caveolin-1 expression in breast cancer samples. A: Breast cancer sample without expression of Caveolin-1 in the epi-
thelial tumor component. In contrast, expression of Caveolin-1 can be seen in myoepithelial cells as well as endothelial cells of 
entrapped vessels, serving as internal positive control (100× magnification). B: Breast cancer sample with strong expression of 
Caveolin-1 in the epithelial tumor component (400× magnification)World Journal of Surgical Oncology 2007, 5:110 http://www.wjso.com/content/5/1/110
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logical factors significantly correlated with Caveolin-1
expression, with the exception of positive correlation
between Caveolin-1 expression and multifocality (p =
0.008) (Table 3). We further examined the distribution of
Caveolin-1 expression among distinct histological sub-
types of breast cancer. Correlation analysis regarding his-
tological subtypes did not reveal a significant correlation
of any of these with Caveolin-1 expression status.
Survival analysis
There were no significant differences between Caveolin-1
positive and Caveolin-1-negative cases with respect to sur-
vival. Mean DFS was 78 months (95%CI 67–95) in Cave-
olin-1 positive as compared to 82 months (95%CI 72–93)
in Caveolin-1 negative patients (p = 0.66) (Figure 2A).
Mean OS was 87 months (95%CI 79–96) in the Caveolin-
1 positive and 84 months (95%CI 70–98) in the Caveo-
lin-1 negative group (p = 0.72) (Figure 2B). Subgroup
analysis according to clinical and pathological parameters
as well as to different treatment did not reveal any prog-
nostic significance of Caveolin-1 expression (data not
shown).
Discussion
Since its first description as a major v-Src-substrate in Rous
sarcoma virus-transformed chicken embryo fibroblasts,
Caveolin-1 has been considered as a presumable mediator
of transformation by oncogenic tyrosine kinases [22]. The
contribution of Caveolin-1 to carcinogenesis and tumour
progression has been intensively evaluated.
In order to examine the potential clinical relevance of
Caveolin-1 in premalignant and malignant breast disease,
we studied Caveolin-1 protein expression in tissue probes
of healthy breast tissue, benign breast disease, DCIS, and
invasive breast cancer, using immunohistochemistry. We
found Caveolin-1 expression in epithelial tumour cells in
32 of 109 cases (29.4%) of invasive breast carcinomas. In
contrast, when evaluating 108 cases of DCIS specimens,
236 cases of benign breast disease and five cases of healthy
breast tissue, no Caveolin-1 expression could be found in
the epithelial component. Caveolin-1 expression was con-
sistently detected in ductal and lobular myoepithelial
cells, in vascular smooth muscle cells, and in endothelial
cells in non-malignant breast tissue samples, which is in
concordance with previous reports [14,21].
Several comprehensive immunohistochemical studies
have reported on Caveolin-1 expression in human breast
cancer; Yang et al.[23], examined Caveolin-1 protein
expression in 15 cases of invasive breast cancer, 15 cases
of intraductal breast cancer, and 9 cases of lymph node
metastasis. They reported significantly higher expression
of Caveolin-1 in both intraductal carcinomas (p > 0.001)
and infiltrating ductal carcinomas (93.3%, p < 0.001) as
well as in lymph node metastases (p < 0.001) relative to
normal breast epithelium. However, even in normal
breast epithelial cells, minimal staining was observed. In
contrast, Hurlstone et al.[14], supported our observations
in that they could not detect Caveolin-1 expression within
the epithelial cell component of human mammary nor-
mal ducts or terminal ductal lobular units of 10 breast
reduction specimens. Instead, high Caveolin-1 expression
levels were again observed in mammary myoepithelial
cells. In the most recent immunohistochemical study,
Savage et al.[21], studied the frequency and cellular distri-
bution of Caveolin-1 expression in normal breast, benign
breast lesions, breast cancer precursors, and breast carci-
nomas. Using a monoclonal antibody, the authors cor-
roborated our results in that no expression of Caveolin-1
could be observed in the epithelial cell component of nor-
mal breast tissue or in luminal epithelial cells of benign
breast lesions such as radial scars. However, luminal epi-
thelial cells demonstrated Caveolin-1 expression in
13.4% of DCIS and 9.4% of invasive breast cancer speci-
mens. The authors observed an inverse correlation
between Caveolin-1 expression and expression of ER, PR,
HER2, and cyclin D1, as well as an association with the
expression of EGFR, cytokeratins 5/6, 14, and 17, high
MIB-1 expression, and p53 expression. Furthermore, they
described a significant association between Caveolin-1
expression and both shorter disease-free and overall sur-
vival as well as with the so-called 'basal-like' immunophe-
notype, which also has been repeatedly associated with
adverse clinical outcome [21]. Interestingly, an associa-
tion between basal-like phenotype and Caveolin-1 expres-
sion has been described in another report. Pinilla et
al.[24], examined Caveolin-1 expression in 509 cases of
sporadic and 47 cases of hereditary breast cancers using a
monoclonal Caveolin-1 antibody. Caveolin-1 expression
was observed among 4.6% of sporadic cases, but among
Table 2: Immunohistochemical analysis of Caveolin-1 expression 
in primary human breast carcinomas
Caveolin-1 
expression score 
(semiquantitative)
frequency (n) percentage (%)
07 7 7 0 . 6
12 4 2 2 . 0
26 5 . 5
32 1 . 9
Total 109 100.0
negative § 77 70.6
positive # 32 29.4
$ all tumours with a Caveolin-1 expression score of 0;
# all tumours with a Caveolin-1 expression score of 1 – 3World Journal of Surgical Oncology 2007, 5:110 http://www.wjso.com/content/5/1/110
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as many as 10.6% of hereditary cases. Caveolin-1 positiv-
ity was again significantly associated with lack of ER, PR,
and HER2 expression and presence of cytokeratin 5/6 and
EGFR expression. Lack of expression of ER and HER2
expression and presence of cytokeratin 5/6 and/or EGFR
expression were taken as surrogate markers indicating a
basal-like phenotype. Accordingly, 52% of Caveolin-1
positive cases were classified as basal-like subtype. These
results are in striking contrast to observation by Sagara et
al., The group examined 162 breast cancer specimens
using the same monoclonal anti-Caveolin-1 antibody and
realtime-PCR. They described a significant positive corre-
Table 3: Correlation analysis of Caveolin-1 expression with clinical and pathological variables in primary breast cancer patients. 
Included are only cases in both Caveolin-1 expression status as well as clinical and pathological variable were available
clinical and pathological variables Caveolin-1 positive/all tumours (%) p (χ2-test)
ER negative 15/41 (36.6) 0.204
positive 16/64 (25.0)
PR negative 20/65 (30.8) 0.721
positive 11/40 (55.0)
HER2 negative 28/98 (28.6) 0.320
positive 4/9 (44.4)
Mib1 < 20% 15/39 (38.4) 0.143
≥ 20% 17/68 (25.0)
pT-stage T1/2 22/80 (27.5) 0.476
T3/4 10/29 (34.5)
pN-stage negative 18/60 (30.0) 0.981
positive 14/47 (29.8)
pM-stage negative 29/94 (30.9) 0.391
positive 3/15 (20.0)
tumour grade 1 1/6 (16.7) 0.740
2 17/59 (28.8)
3 14/44 (31.8)
multifocality no 19/83 (22.9) 0.008
yes 13/26 (50.0)
inflammatory no 30/102 (29.4) 0.962
yes 2/7 (28.6)
lymphangiosis carcinomatosa no 22/82 (26.8) 0.312
yes 10/27 (37.0)World Journal of Surgical Oncology 2007, 5:110 http://www.wjso.com/content/5/1/110
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lation between Caveolin-1-mRNA expression in breast
cancer and positive oestrogen receptor-status as well as
reduced tumour size [20]. In our study, neither oestrogen
receptor status, nor tumour stage, nor other clinical or
pathological parameters, besides multifocality (p =
0.008), correlated with Caveolin-1 expression. Further-
more, no significant correlation with either disease free
survival or overall survival could be demonstrated.
Choice of primary antibody and scoring system has been
shown to have a substantial impact on the results of
immunoreactivity. For example, Kersting et al., deter-
mined epidermal growth factor receptor (EGFR) immu-
noreactivity in 302 cases of soft tissue sarcomas using five
different commercially available antibodies, and EGFR
amplification status in 283 cases using fluorescence in situ
hybridisation (FISH). Depending on the antibody and
scoring method used, EGFR expression frequency varied
between 0.3% and 52.9%. EGFR gene amplification was
determined in 3.5% of tumours showed and correlated
with EGFR expression for only three antibodies [25]. Of
note, Yang et al., used a polyclonal antiserum to deter-
mine Caveolin-1 expression status in human prostate and
breast malignancies. They reported positive staining in as
many as 80% of cases of intraductal carcinomas and also
minimal Caveolin-1 expression in normal breast epithe-
lium. In contrast, when using a monoclonal antibody,
Hurlstone et al., corroborated our results, in that no Cave-
olin-1 expression was observed among normal breast epi-
thelial cells [14]. Different scoring methods might explain
some of the discrepancies between our results and those
of Savage et al.[21]. The group applied a semiquantitative
consensus score of both distribution and intensity of
Caveolin-1 immunostaining. Based on a cutoff score of ≥
4 they reported Caveolin-1 expression in 9.4% of primary
breast cancers. In our study we applied a 4-tired semi-
quantitative score to describe intensity of Caveolin-1
expression. In face of the lack of Caveolin-1 expression in
normal breast epithelial cells, we considered any Caveo-
lin-1 staining as positive and combined weak, moderate
and strong Caveolin-1 expression (scores "1" to "3") to
represent Caveolin-1 positivity. Thus, we observed Caveo-
lin-1 expression in 32 of 109 cases of invasive breast car-
cinomas (29.4%). However, if we had only regarded
moderate and strong expression, we would have observed
Caveolin-1 expression in only 7.3% of cases, which is in
the range of the results by Savage et al.[21].
Interestingly, Savage et al., reported Caveolin-1 immunos-
taining in 2 of 15 cases (13.4%) of DCIS [21]. This is in
striking contrast to our results. We examined 108 cases of
DCIS and could not find Caveolin-1 positivity among
these cases. In concordance with the methodology of Sav-
age et al., entrapped blood vessels were used as internal
positive controls in order to ensure robustness of the data.
The TMAs in this study included endothelial cells in both
Kaplan Meier estimates for OS and DFS stratified by Caveolin-1 expression Figure 2
Kaplan Meier estimates for OS and DFS stratified by Caveolin-1 expression. A: Mean DFS in the Caveolin-1 positive 
and the Caveolin-1 negative group was 82 months (95% Confidence Interval 72–93 months) and 78 months (95%CI 62–95; log 
rank: p = 0.66), respectively. B: Mean OS in the Caveolin-1 positive and the Caveolin-1 negative group was 87 months (95%CI 
79–96) and 84 months (95%CI 70–98; p = 0.72), respectively.World Journal of Surgical Oncology 2007, 5:110 http://www.wjso.com/content/5/1/110
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malignant tumour specimens as well as adjacent normal
breast tissue. Endothelial cells were consistently found to
be Caveolin-1 positive.
The role of Caveolin-1 in mammary carcinogenesis is still
far from being completely understood. Scientific evidence
of a tumour suppressive role of Caveolin-1 in breast can-
cer supported by some researchers [26] is contrasted by
recent results which strengthen the role of Caveolin-1
overexpression to promote certain steps of tumourigene-
sis: Caveolin-1 has been shown to inhibit anoikis in
MCF7 breast cancer cells [27]. Furthermore, Caveolin-1
has been demonstrated to mediate medroxyprogesterone
acetate-(MPA)-induced breast cancer cell growth [28].
Inflammatory breast cancer represents a highly aggressive
form of invasive breast cancer. Among these cancers,
Caveolin-1 expression is upregulated compared to expres-
sion levels in non-inflammatory carcinomas [29]. In face
of this controversy one has to assume that the role of
Caveolin-1 as both tumour suppressor and promoter
might be context-depending. While being downregulated
in early stage malignancies and thereby mediating growth
promoting effects, upregulation of Caveolin-1 in late stage
disease might promote resistance against chemotherapeu-
tic agents in colon cancer as well as metastatic properties
in prostate cancer [30]. It seems reasonable that both the
conflicting data on Caveolin-1 expression frequencies and
the lack of a clear prognostic impact in breast cancer mir-
ror the variety of functions, which Caveolin-1 is believed
to obtain in breast cancer pathogenesis. Caveolin-1 has
been shown to determine the function of caveolae as a
platform to preassemble distinct components of cellular
pathways, and therefore both to render signal transduc-
tion more efficient and to enable appropriate interaction
between distinct pathways [31]. This allows placing the
protein components in close proximity to each other.
Thus, its distinct role in cellular processes may depend on
the combination of proteins expressed in the cells rather
than on Caveolin-1 expression itself.
Importantly, recent results have revealed a potential ther-
apeutic relevance of Caveolin-1 since the Caveolin-1-pro-
moter has been hypothesized to be used as a specific target
in gene therapy of prostate carcinoma in the nearer future
[32]. Bortezomib, an antibody against the 26-S-proteas-
ome, has been shown to target Caveolin-1 among a vari-
ety of other proteins in studies in various cancer entities
[33].
Conclusion
In our immunohistochemical study, we found significant
Caveolin-1 expression in one third of invasive breast car-
cinomas, whereas neither normal breast tissue, nor
benign breast disease, nor DCIS showed relevant Caveo-
lin-1 expression. Furthermore, we demonstrated that
Caveolin-1 expression alone does not show any clear-cut
prognostic or predictive properties. We hypothesize that
instead of being an independent prognostic factor alone,
Caveolin-1 might exhibit a more complex function that
needs to be evaluated in context with the co-expressed
proteins as well as in view of the respective disease stage.
This might finally explain the conflicting results described
in the scientific literature. Further studies are warranted to
understand the role of Caveolin-1 expression in the dis-
ease course of breast cancer as well as its potential as a
therapeutic target.
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